Back to Authors

Noseworthy, John H.

A5079266665 | I1330342723

Mayo Clinic

Mayo Clinic

Citations 38

Upcoming Changes for Authors

Neurology | December 10, 2007 | Volume: 69 | Issue: 24 | Pages: 2192-2192

10.1212/01.wnl.0000298808.89852.15

Global issue

Neurology | October 22, 2007 | Volume: 69 | Issue: 17 | Pages: 1644-1644

10.1212/01.wnl.0000289090.14598.07

Neurology ® podcasts

Neurology | September 4, 2007 | Volume: 69 | Issue: 10 | Pages: 948-948

10.1212/01.wnl.0000281541.78240.9e

Neurology®

Neurology | July 2, 2007 | Volume: 69 | Issue: 1 | Pages: 9-11

10.1212/01.wnl.0000271095.90695.8a

Our commitment to rapid publication

Neurology | April 23, 2007 | Volume: 68 | Issue: 17 | Pages: 1331-1332

10.1212/01.wnl.0000263475.96501.3a

How much can we learn from long-term extension trials in multiple sclerosis?

Neurology | September 25, 2006 | Volume: 67 | Issue: 6 | Pages: 930-931

10.1212/01.wnl.0000241080.31577.df | PMID 17000954

MRI findings of rapidly progressive ophthalmoplegia and blindness in mucormycosis

Neurology | May 22, 2006 | Volume: 66 | Issue: 10 | Pages: No page available

10.1212/01.wnl.0000204231.85308.7e | PMID 16717200

Multiple Sclerosis

Annual Review of Medicine | July 27, 2002 | Volume: 53 | Issue: 1 | Pages: 285-302

10.1146/annurev.med.53.082901.103909 | PMID 11818475

▪ Abstract Multiple sclerosis (MS) is a common inflammatory disease of the central nervous system (CNS). Diagnosis rests upon identifying typical clinical symptoms and interpreting supportive laboratory and radiological investigations. The etiology is unknown; however, strong evidence suggests that MS is an autoimmune disease directed against CNS myelin or oligodendrocytes. Genetic factors are important in the development of MS. Contributing environmental determinants (possibly including infectious agents) appear important but remain unidentified. Both cell-mediated and humorally mediated immune mechanisms contribute to pathological injury. Axonal damage occurs in addition to demyelination and may be the cause of later permanent disability. Distinct pathological subtypes may differentiate among patients with MS. Treatment is directed at acute attacks (with corticosteroids) and reduction of attack frequency (primarily with type-1 β interferons and glatiramer acetate). Research into the causes and treatments of MS has expanded our knowledge of this disease and promises improved care for MS patients in the future.